Press release
Autoimmune Gastrointestinal Dysmotility Market Size Projected To Reach 2.3 Billion By 2034 With A Cagr Of 5.9%
Autoimmune Gastrointestinal Dysmotility
What Is the Projected Growth of the Autoimmune Gastrointestinal Dysmotility Market?
In recent years, there has been a significant growth in the market size for autoimmune gastrointestinal dysmotility. It is expected to surge from $1.73 billion in 2024 to $1.83 billion by the year 2025, experiencing a compound annual growth rate (CAGR) of 6.0%. Several factors have contributed to the growth in the past few years, such as the escalating unawareness about rare diseases, an increase in inadequate diagnostic procedures, a rise in misdiagnosis with other gi disorders, a lack of targeted therapies, and a slowdown in research progress.
The market for autoimmune gastrointestinal dysmotility is projected to witness robust expansion in the coming years, escalating to a value of $2.30 billion in 2029 with a compound annual growth rate (CAGR) of 5.9%. This surge during the forecasted period can be attributed to factors such as the increasing prevalence of autoimmune diseases, enhancements in diagnostic methodologies, a rise in healthcare spending, a larger number of rare disease registries, and improved clinician education. The forecast period will also see significant trends including technological advancement in diagnostics, groundbreaking strides in immunotherapy, advances in neurogastroenterology research, increased R&D in motility modulators, and adoption of tailored treatment methods.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp
What Are the Different Autoimmune Gastrointestinal Dysmotility Market Segments?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented -
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
What Are the Primary Drivers Shaping the Autoimmune Gastrointestinal Dysmotility Market?
The escalating incidence of autoimmune disorders is anticipated to stimulate the growth of the autoimmune gastrointestinal dysmotility market. Autoimmune diseases occur when the body's immune system erroneously attacks its healthy cells, tissues, or organs instead of safeguarding them from infections and external elements. The upward trend of autoimmune disorders is essentially attributed to a mix of genetic vulnerability and environmental initiators, which collectively hinder the immune system control, heightening the probability of the body assaulting its tissues. Autoimmune gastrointestinal dysmotility facilitates the recognition and control of underlying autoimmune disorders by demonstrating immune-caused harm to the enteric nervous system, associating gastrointestinal symptoms to systemic autoimmune behavior. For instance, in November 2024, a study survey conducted by Versorgungsatlas.de among 73,241,305 individuals in 2022 revealed that roughly 6,304,340 were diagnosed with a minimum of one autoimmune disease, leading to an unrefined prevalence rate of 8.61. Thus, the escalating incidence of autoimmune disorders is propelling the autoimmune gastrointestinal dysmotility market growth. The amplified focus on personalized medicine foresees an upward trend for the autoimmune gastrointestinal dysmotility market, thanks to the strides made in bespoke treatment strategies for autoimmune conditions. Personalized medicine is a medical approach that customizes treatment and prevention plans according to an individual's distinct genetic composition, lifestyle, and surroundings. The emergence of personalized medicine is chiefly credited to advancements in genomics, facilitating the accurate identification of genetic variations and customized treatments for individuals. The concept of personalized medicine supports the treatment of autoimmune gastrointestinal dysmotility by adapting therapies to an individual's genetic constitution and specific disease features, enhancing treatment efficiency while reducing side effects. This method delivers more precise solutions for managing intricate gastrointestinal disorders. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable escalation from the 12 approved in 2022. Therefore, the amplified focus on personalized medicine propels the growth of the autoimmune gastrointestinal dysmotility market.
Which Companies Are Leading in the Autoimmune Gastrointestinal Dysmotility Market?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
What Trends Are Expected to Dominate the Autoimmune Gastrointestinal Dysmotility Market in the Next 5 Years?
Leading businesses in the autoimmune gastrointestinal dysmotility market are strategically partnering to offer digital therapy solutions for managing conditions related to this disorder. Such strategic alliances help improve the care for autoimmune gastrointestinal dysmotility by providing a virtual-first healthcare system, combining various disciplines, enhancing symptom management, ease of access to care, and cost-efficient services. For example, in March 2022, Solera Health, a digital health enterprise based in the US, established a partnership with Oshi Health, a virtual gastrointestinal care firm, and Vivante Health, another US-based digital health business. This cooperation will deliver superior digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The partnership seeks to enhance patient access to specialized care and improve the overall effectiveness of treatments for individuals suffering from gastrointestinal disorders.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report
What Are the Top Revenue-Generating Geographies in the Autoimmune Gastrointestinal Dysmotility Market?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Autoimmune Gastrointestinal Dysmotility Market?
2. What is the CAGR expected in the Autoimmune Gastrointestinal Dysmotility Market?
3. What Are the Key Innovations Transforming the Autoimmune Gastrointestinal Dysmotility Industry?
4. Which Region Is Leading the Autoimmune Gastrointestinal Dysmotility Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autoimmune Gastrointestinal Dysmotility Market Size Projected To Reach 2.3 Billion By 2034 With A Cagr Of 5.9% here
News-ID: 4061128 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for Autoimmune
Autoimmune Polyglandular Syndrome Market analysis reveals CAGR of 6.20 percent t …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Autoimmune Polyglandular Syndrome Type 1 Market - (By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)),…
Reshaping Autoimmune Therapy Landscape: Protheragen Announces Small Molecule Dru …
Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune diseases.
New York, USA - Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune conditions. From target identification to preclinical studies, Protheragen leverages its expertise in small molecule drug design and development to offer tailored services that provide biotech and pharmaceutical companies…
Autoimmune Disease Diagnosis Market - Strength in Knowledge, Defying Autoimmune …
Newark, New Castle, USA: The "Autoimmune Disease Diagnosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Autoimmune Disease Diagnosis Market: https://www.growthplusreports.com/report/autoimmune-disease-diagnosis-market/7616
This latest report researches the industry structure,…
Autoimmune Drugs Market: Understanding How They Work and Their Importance in Tre …
Allied Market Research recently said Autoimmune diseases are a group of disorders in which the body's immune system attacks its own healthy tissues, mistaking them for foreign invaders. These diseases can affect any part of the body, including the joints, skin, and organs. They can be debilitating, chronic, and sometimes life-threatening. Autoimmune drugs are medications that help to suppress or modulate the immune system's response to prevent it from attacking…
Autoimmune Disease Diagnostics Market: Growing Awareness among People about Auto …
According to the recent report by Transparency Market Research, the global autoimmune disease diagnostics market has a highly consolidated scenario. The market is dominated by a handful of players. However, these players have a stronghold over the dynamics of market and pose a great challenge for any new entrant to set its foot in the market.
Read Report Overview - https://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html
To reduce effects of such hindrances, the new entrants are…
Autoimmune Disease Therapeutics Market Boost due to increase in incidence of aut …
According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan
Autoimmune disease therapeutics include…
